Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Blood Advances
|
October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Haematologica
|
February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)
Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 13, 2021
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group
Mauricette Michallet, Mohamad Sobh, Stephane Morisset, et al.
Cancer Medicine
|
December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
Louise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Leukemia
|
September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Blood
|
December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AML
Jad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
American Journal of Hematology
|
February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study
Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
Blood Neoplasia
|
June 2, 2025
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
Catia Simoes, Carmen Gonzalez, François Vergez, et al.
NEJM Evidence
|
June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML Therapy
Mathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
Leukemia
|
May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement
Benoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Blood Advances
|
October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Haematologica
|
February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)
Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 13, 2021
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group
Mauricette Michallet, Mohamad Sobh, Stephane Morisset, et al.
Cancer Medicine
|
December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
Louise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Leukemia
|
September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Blood
|
December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AML
Jad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
American Journal of Hematology
|
February 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study
Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, et al.
Blood Neoplasia
|
June 2, 2025
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
Catia Simoes, Carmen Gonzalez, François Vergez, et al.
NEJM Evidence
|
June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML Therapy
Mathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
Leukemia
|
May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement
Benoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Page
of 10